Preview

Современная ревматология

Расширенный поиск

Анальгетическое лечение с использованием системного а л горитма

https://doi.org/10.14412/1996-7012-2015-2-37-50

Полный текст:

Аннотация

Контроль мышечно-скелетной боли (МСБ) является важной составляющей комплексного лечения системных воспалительных ревматических заболеваний, таких как ревматоидный артрит и спондилоартриты, и главным направлением терапии остеоартроза и неспецифической боли в спине. Развитие боли связано с рядом патогенетических механизмов: локальным воспалением, вовлечением элементов связочного аппарата, стойким мышечным напряжением, биомеханическими нарушениями, дисфункцией ноцицептивной системы. Это определяет необходимость комплексного подхода при проведении анальгетической терапии с комбинированным применением препаратов, обладающих различным механизмом обезболивающего действия. В настоящем обзоре рассматриваются «мишени» фармакотерапии МСБ и основные группы лекарственных препаратов, которые могут на них воздействовать. В статье предлагается алгоритм проведения обезболивающей терапии, основанный на диагностике отдельных элементов патогенеза хронической МСБ и последовательной оценке результатов лечения.

Об авторах

А. Е. Каратеев
ФГБНУ НИИР им. В.А. Насоновой, Москва, Россия 115522, Москва, Каширское шоссе, 34А
Россия


Л. И. Алексеева
ФГБНУ НИИР им. В.А. Насоновой, Москва, Россия 115522, Москва, Каширское шоссе, 34А
Россия


Литература

1. Яхно НН, Кукушкин МЛ, редакторы. Боль (практическое руководство для врачей). Москва: Издательство РАМН; 2012. 512 c. [Yakhno NN, Kukushkin ML, editors. Bol' (prakticheskoe rukovodstvo dlya vrachei) [Pain (a practical guide for doctors)]. Moscow: Izdatel'stvo RAMN; 2012. 512 p.]

2. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2163–96. doi: 10.1016/S0140–6736(12)61729–2.

3. Harker J, Reid KJ, Bekkering GE, et al. Epidemiology of chronic pain in Denmark and Sweden. Pain Res Treat. 2012;2012:371248. doi: 10.1155/2012/371248. Epub 2012 May 23..

4. Gore M, Sadosky A, Stacey BR, et al. The burden of chronic low back pain: clinical comorbidities, treatment patterns, and health care costs in usual care settings. Spine (Phila Pa 1976). 2012 May 15;37(11):E668–77. doi: 10.1097/BRS.0b013e318241e5de.

5. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006 May;10(4):287–333. Epub 2005 Aug 10.

6. Friedly J, Chan L, Deyo R. Increases in lumbosacral injections in the Medicare population: 1994 to 2001. Spine (Phila Pa 1976). 2007 Jul 15;32(16):1754–60.

7. Deyo RA, Von Korff M, Duhrkoop D. Opioids for low back pain. BMJ. 2015 Jan 5;350:g6380. doi: 10.1136/bmj.g6380.

8. Deyo R, Mirza S, Turner J, Martin B. Overtreating chronic back pain: time to back off? J Am Board Fam Med. 2009 Jan-Feb;22(1):62–8. doi: 10.3122/jabfm.2009.01.080102.

9. Murray CJ, Atkinson C, Bhalla K, et al. The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. JAMA. 2013 Aug 14;310(6):591–608. doi: 10.1001/jama.2013.13805.

10. Насонова ВА, Фоломеева ОМ, Эрдес ШФ. Ревматические заболевания в Российской Федерации в начале XXI века глазами статистики. Терапевтический архив. 2009;(6):5–10. [Nasonova VA, Folomeeva OM, Erdes ShF. Rheumatic diseases in the Russian Federation in the beginning of the XXI century through the eyes of statistics. Terapevticheskii arkhiv. 2009;(6):5–10. (In Russ.)].

11. Эрдес ШФ, Фоломеева ОМ. Ревматические заболевания и инвалидность взрослого населения Российской Федерации. Научно-практическая ревматология. 2007;(4):4–9. [Erdes ShF, Folomeeva OM. Rheumatic diseases and disability of the adult population of the Russian Federation. Nauchno-prakticheskaya revmatologiya = Rheumatology science and practice. 2007;(4):4–9. (In Russ.)].

12. Каратеев АЕ. Болезни костно-мышечной системы в практике 2102 врачей разных специальностей: структура патологии и мнение специалистов об эффективности НПВП (предварительные данные эпидемиологического исследования КОРОНА-2). Consilium medicum. 2013;(9):95–100. [Karateev AE. Diseases of the musculoskeletal system in practice of 2102 doctors of different specialties: the structure of pathology and the opinions of experts about the effectiveness of NSAIDs (preliminary data from CORONA-2 epidemiological survey). Consilium medicum. 2013;(9):95–100. (In Russ.)].

13. Каратеев АЕ, Попкова ТВ, Новикова ДС и др. Оценка риска желудочно-кишечных и сердечно-сосудистых осложнениищ, ассоциированных с приемом нестероидных противовоспалительных препаратов в популяции СНГ: предварительные данные эпидемиологического исследования КОРОНА-2. Научно-практическая ревматология. 2014;52(6):600–6. [Karateev AE, Popkova TV, Novikova DS, et al. Assessment of risk for gastrointestinal and cardiovascular complications associated with the use of nonsteroidal anti-inflammatory drugs in the CIS population: preliminary data of the CORONA-2 epidemiological survey. Nauchno-prakticheskaya revmatologiya = Rheumatology science and practice. 2007;(4):4–9. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484- 2014-600-606

14. Igarashi A, Kikuchi S, Konno S, Olmarker K. Inflammatory cytokines released from the facet joint tissue in degenerative lumbar spinal disorders. Spine (Phila Pa 1976). 2004 Oct 1;29(19):2091–5.

15. Genevay S, Finckh A, Payer M, et al. Elevated levels of tumor necrosis factor-alpha in periradicular fat tissue in patients with radiculopathy from herniated disc. Spine (Phila Pa 1976). 2008 Sep 1;33(19):2041–6. doi: 10.1097/BRS.0b013e318183bb86.

16. Cuellar JM, Golish SR, Reuter MW, et al. Cytokine evaluation in individuals with low back pain using discographic lavage. Spine J. 2010 Mar;10(3):212–8. doi: 10.1016/j.spinee. 2009.12.007.

17. Schaible HG. Mechanisms of chronic pain in osteoarthritis. Curr Rheumatol Rep. 2012 Dec;14(6):549–56. doi: 10.1007/s11926-012-0279-x.

18. Walsh DA, Bonnet CS, Turner EL, et al. Angiogenesis in the synovium and at the osteochondral junction in osteoarthritis. Osteoarthritis Cartilage. 2007 Jul; 15(7):743–51. Epub 2007 Mar 21.

19. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum. 2001 Jun;44(6):1237–47.

20. Alvarez-Soria MA, Largo R, Santillana J, et al. Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Ann Rheum Dis. 2006 Aug;65(8):998–1005. Epub 2006 Feb 13.

21. McCarberg BH, Ruoff GE, Tenzer- Iglesias P, Weil AJ. Diagnosis and treatment of low-back pain because of paraspinous muscle spasm: a physician roundtable. Pain Med. 2011 Nov;12 Suppl 4:S119–27. doi: 10.1111/j.1526-4637.2011.01253.x.

22. Lund JP, Donga R, Widmer CG, Stohler CS. The pain-adaptation model: a discussion of the relationship between chronic musculoskeletal pain and motor activity. Can J Physiol Pharmacol. 1991 May;69(5):683–94.

23. Roland M. A critical review of the evidence for pain-spasm-pain cycle in spinal disorders. Clin Biomech (Bristol, Avon). 1986 May;1(2):102–9. doi: 10.1016/0268- 0033(86)90085-9.

24. Iglesias-Gonzalez JJ, Munoz-Garcia MT, Rodrigues-de-Souza DP, et al. Myofascial trigger points, pain, disability, and sleep quality in patients with chronic nonspecific low back pain. Pain Med. 2013 Dec;14(12):1964–70. doi: 10.1111/pme.12224. Epub 2013 Aug 15.

25. Ramsook RR, Malanga GA. Myofascial low back pain. Curr Pain Headache Rep. 2012 Oct;16(5):423–32. doi: 10.1007/s11916-012-0290-y.

26. Fisher NM, Pendergast DR. Reduced muscle function in patients with osteoarthritis. Scand J Rehabil Med. 1997 Dec;29(4):213–21.

27. Arokoski MH, Arokoski JP, Haara M, et al. Hip muscle strength and muscle cross sectional area in men with and without hip osteoarthritis. J Rheumatol. 2002 Oct;29(10):2185–95.

28. Blume C, Wang SS. Comparison of changes in supraspinatus muscle thickness in persons with subacromial impingement syndrome and asymptomatic adults. Physiother Theory Pract. 2014 Nov;30(8):544–51. doi: 10.3109/09593985.2014.902522. Epub 2014 Mar 28.

29. Silldorff MD, Choo AD, Choi AJ, et al. Effect of supraspinatus tendon injury on supraspinatus and infraspinatus muscle passive tension and associated biochemistry. J Bone Joint Surg Am. 2014 Oct 15;96(20):e175. doi: 10.2106/JBJS.M.01315.

30. Thomopoulos S, Parks WC, Rifkin DB, Derwin KA. Mechanisms of tendon injury and repair. J Orthop Res. 2015 Jan 29. doi: 10.1002/jor.22806. Epub ahead of print.

31. Millar NL, Hueber AJ, Reilly JH, et al. Inflammation is present in early human tendinopathy. Am J Sports Med. 2010 Oct;38(10):2085–91. doi: 10.1177/0363546510372613. Epub 2010 Jul 1.

32. McGonagle D, Benjamin M. Entheses, entehesitis and enthesopathy. Report of heumatic diseases, series 6, autumn 2009, №4. На сайте: www.arc.org.uk/arthinfo/rdr.asp 33. Benjamin M., McGonagle D. Histopathologic Changes at «Synovio- Entheseal Complexes» Suggesting a Novel Mechanism for Synovitis in Osteoarthritis and Spondylarthritis. Arthritis Rheum. 2007 Nov;56(11):3601–9.

33. Gotoh M, Hamada K, Yamakawa H, et al. Interleukin-1-induced glenohumeral synovitis and shoulder pain in rotator cuff diseases. J Orthop Res. 2002 Nov;20(6):1365–71.

34. Voloshin I, Gelinas J, Maloney MD, et al. Proinflammatory cytokines and etalloproteases are expressed in the subacromial bursa in patients with rotator cuff disease. Arthroscopy. 2005 Sep;21(9):1076.e1–1076.e9.

35. Haviv B, Bronak S, Thein R. The complexity of pain around the knee in patients with osteoarthritis. Isr Med Assoc J. 2013 Apr;15(4):178–81.

36. Felson DT. Osteoarthritis as a disease of mechanics. Osteoarthritis Cartilage. 2013 Jan;21(1):10–5. doi: 10.1016/j.joca.2012.09.012. Epub 2012 Oct 4.

37. Edmonds S. Therapeutic targets for osteoarthritis. Maturitas. 2009 Jul 20;63(3):191–4. doi: 10.1016/j.maturitas. 2009.03.015. Epub 2009 May 6.

38. Felson DT. The sources of pain in knee osteoarthritis. Curr Opin Rheumatol. 2005 Sep;17(5):624–8.

39. Staud R. Evidence for shared pain mechanisms in osteoarthritis, low back pain, and fibromyalgia. Curr Rheumatol Rep. 2011 Dec;13(6):513–20. doi: 10.1007/s11926-011- 0206-6.

40. Tsao H, Tucker KJ, Coppieters MW, Hodges PW. Experimentally induced low back pain from hypertonic saline injections into lumbar interspinous ligament and erector spinae muscle. Pain. 2010 Jul;150(1):167–72. doi: 10.1016/j.pain.2010.04.023. Epub 2010 May 26.

41. Panjabi MM. A hypothesis of chronic back pain: ligament subfailure injuries lead to muscle control dysfunction. Eur Spine J. 2006 May;15(5):668–76. Epub 2005 Jul 27.

42. Longo UG, Berton A, Khan WS, et al. Histopathology of rotator cuff tears. Sports Med Arthrosc. 2011 Sep;19(3):227–36. doi: 10.1097/JSA.0b013e318213bccb.

43. Ko JY, Wang FS. Rotator cuff lesions with shoulder stiffness: updated pathomechanisms and management. Chang Gung Med J. 2011 Jul-Aug;34(4):331–40.

44. Raastad J, Reiman M, Coeytaux R, et al. The association between lumbar spine adiographic features and low back pain: A systematic review and meta-analysis. Semin Arthritis Rheum. 2015 Apr;44(5):571–85. doi: 10.1016/j.semarthrit.2014.10.006. Epub 2014 Dec 8.

45. de Schepper EI, Damen J, van Meurs JB, et al. The association between lumbar disc degeneration and low back pain: the influence of age, gender, and individual radiographic features. Spine (Phila Pa 1976). 2010 Mar 1;35(5):531–6. doi: 10.1097/BRS.0b013e3181aa5b33.

46. Scheele J, de Schepper EI, van Meurs JB, et al. Association between spinal morning stiffness and lumbar disc degeneration: the Rotterdam Study. Osteoarthritis Cartilage. 2012 Sep;20(9):982–7. doi: 10.1016/j.joca. 2012.05.011. Epub 2012 Jun 12.

47. Beresford ZM, Kendall RW, Willick SE. Lumbar facet syndromes. Curr Sports Med Rep. 2010 Jan-Feb;9(1):50–6. doi: 10.1249/JSR.0b013e3181caba05.

48. Cohen SP, Raja SN. Pathogenesis, diagnosis, and treatment of lumbar zygapophysial (facet) joint pain. Anesthesiology. 2007 Mar;106(3):591–614.

49. Туровская ЕФ, Алексеева ЛИ, Филатова ЕГ. Современные представления о патогенетических механизмах боли при остеоартрозе. Научно-практическая ревматология. 2014;52(4):438–44. [Turovskaya EF, Alekseeva LI, Filatova EG. Current ideas about the pathogenetic mechanisms of pain in osteoarthrosis. Nauchno-prakticheskaya revmatologiya = Rheumatology science and practice. 2014;52(4):438–44. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2014-438-444

50. Mease PJ, Hanna S, Frakes EP, Altman RD. Pain mechanisms in osteoarthritis: understanding the role of central pain and urrent approaches to its treatment. J Rheumatol. 2011 Aug;38(8):1546–51. doi: 10.3899/jrheum.100759. Epub 2011 Jun 1.

51. Hochman JR, French MR, Bermingham SL, Hawker GA. The nerve of osteoarthritis pain. Arthritis Care Res (Hoboken). 2010 Jul;62(7):1019–23. doi: 10.1002/acr.20142.

52. Fishbain DA, Cole B, Lewis JE, Gao J. What is the evidence that neuropathic pain is present in chronic low back pain and soft tissue syndromes? An evidence-based structured review. Pain Med. 2014 Jan;15(1):4–15. doi: 10.1111/pme.12229. Epub 2013 Oct 4.

53. Coombes BK, Bisset L, Vicenzino B. Thermal hyperalgesia distinguishes those with severe pain and disability in unilateral lateral epicondylalgia. Clin J Pain 2012;28:595–601.

54. Blondell RD, Azadfard M, Wisniewski AM. Pharmacologic therapy for acute pain. Am Fam Physician. 2013 Jun 1;87(11):766–72.

55. Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry. 2009 May- Jun;31(3):206–19. doi: 10.1016/j.genhosppsych. 2008.12.006. Epub 2009 Mar 4.

56. Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015 Feb 20;8:105–18. doi: 10.2147/JPR.S75160. eCollection 2015.

57. Каратеев АЕ, Насонов ЕЛ, Яхно НН и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;(1):4–23. [Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of nonsteroidal antiinflammatory drugs (NSAIDs) in clinical practice». Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015;(1):4–23. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1996-7012-2015- 1-4-23

58. Moore RA, Moore OA, Derry S, et al. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis. 2010 Feb;69(2):374–9. doi: 10.1136/ard.2009.107805. Epub 2009 Apr 12.

59. Goldstein JL, Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf. 2015 Jan 22;7:31–41. doi: 10.2147/DHPS.S71976. eCollection 2015.

60. Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci. 2013;16(5):821–47.

61. Lemmel EM, Leeb B, De Bast J, Aslanidis S. Patient and physician satisfaction with acec-lofenac: results of the European Observational Cohort Study (experience with aceclofenac for inflammatory pain in daily practice). Aceclofenac is the treatment of choice for patients and physicians in the management of inflammatory pain. Curr Med Res Opin. 2002;18(3):146–53.

62. Dooley M, Spencer CM, Dunn CJ. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351–78.

63. Hаskinsson E., Irani M., Murray F. A large prospective open-label, multi-centre SAMM study, comparing the safety of aceclofenac with diclofenac in patients with rheumatic disease. Eur J Rheumatol Inflam. 2000;17:1–7.

64. Шарапова ЕП, Кашеварова НГ, Аникин СГ и др. Применение новых форм ацеклофенака при остеоартрозе в реальной клинической практике. Современная ревматология. 2014;(1):73-6. [Sharapova EP, Kashevarova NG, Anikin SG, et al. The use of new aceclofenac dosage forms in patients with osteoarthrosis in reallife clinical practice. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2014;(1):73-6. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1996-7012-2014-1-73-76

65. Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk actors: a randomized clinical trial. JAMA. 2014 Dec 17;312(23):2510–20. doi: 10.1001/jama.2014.15690.

66. Brotons C, Benamouzig R, Filipiak KJ, et al. A Systematic Review of Aspirin in Primary Prevention: Is It Time for a New Approach? Am J Cardiovasc Drugs. 2014 Dec 12. Epub ahead of print.

67. Hennekens CH, Dalen JE. Aspirin in the primary prevention of cardiovascular disease: Current knowledge and future research needs. Trends Cardiovasc Med. 2014 ov;24(8):360–6. doi: 10.1016/j.tcm.2014.08.006. Epub 2014 Sep 1.

68. Day RO, Graham GG, Whelton A. The position of paracetamol in the world of analgesics. Am J Ther. 2000 Mar;7(2):51–4.

69. Prescott LF. Paracetamol: past, present and future. Am J Ther. 2000 Mar;7(2):143–7.

70. Towheed TE, Maxwell L, Judd MG, et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004257.

71. Garcia Rodriguez LA, Hernandez-Diaz S. Relative risk of upper gastrointestinal omplications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001 Sep;12(5):570–6.

72. Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, nd the risk of cardiovascular events. Circulation. 2006 Mar 28;113(12):1578–87. Epub 2006 Mar 13.

73. Dedier J, Stampfer MJ, Hankinson SE, et al. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension. 2002 Nov;40(5):604–8; discussion 601–3.

74. Forman JP, Rimm EB, Curhan GC. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med. 2007 Feb 26;167(4):394–9.

75. Ong CK, Seymour RA, Lirk P, Merry AF. Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg. 2010 Apr 1;110(4):1170–9. doi: 10.1213/ANE.0b013e3181cf9281.Epub 2010 Feb 8.

76. McQuay H, Edwards J. Meta-analysis of single dose oral tramadol plus acetaminophen in acute postoperative pain. Eur J Anaesthesiol Suppl. 2003;28:19–22.

77. Cepeda MS, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis: a systematic review and metaanalysis. J Rheumatol. 2007 Mar;34(3):543–55.

78. Rosenberg MT. The role of tramadol ER in the treatment of chronic pain. Int J Clin Pract. 2009 Oct;63(10):1531–43. doi: 10.1111/j.1742-1241.2009.02161.x.

79. Peloso PM, Fortin L, Beaulieu A, et al. Analgesic efficacy and safety of tramadol/ acetaminophen combination tablets (Ultracet) in treatment of chronic low back pain: a multicenter, outpatient, randomized, ouble blind, placebo controlled trial. J Rheumatol. 2004 Dec;31(12):2454–63.

80. Perrot S, Krause D, Crozes P, et al. Efficacy and tolerability of paracetamol/tramadol (325 mg/37.5 mg) combination treatment compared with tramadol (50 mg) monotherapy in pa-tients with subacute low back pain: a multicenter, randomized, double- blind, parallel-group, 10-day treatment study. Clin Ther. 2006 Oct;28(10):1592–606.

81. Tjä derborn M, Jö nsson AK, Ahlner J, Hä gg S. Tramadol dependence: a survey of spontaneously reported cases in Sweden. Pharmacoepidemiol Drug Saf. 2009 Dec;18(12):1192–8. doi: 10.1002/pds.1838.

82. O'Donnell JB, Ekman EF, Spalding WM, et al. The effectiveness of a weak opioid edication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: results from two randomized, oubleblind, 6-week studies. J Int Med Res. 2009 Nov-Dec;37(6):1789–802.

83. Beaulieu AD, Peloso PM, Haraoui B, et al. Once-daily, controlled-release tramadol and sus-tained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized ontrolled tri-al. Pain Res Manag. 2008 Mar- Apr;13(2):103–10.

84. van Tulder MW, Touray T, Furlan AD, et al. Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev 2003;(2):CD004252.

85. Гурак СВ, Парфенов ВА, Борисов КН. Мидокалм в комплексной терапии острой поясничной боли. Боль. 2006;(3):27–30. [Gurak SV, Parfenov VA, Borisov KN. Mydocalm in complex therapy of acute low back pain. Bol'. 2006;(3):27–30. (In Russ.)].

86. Ласло Х, Мелинда М, Жолт С, Иштван З. Лечение острой поясничной боли Мидокалмом. Результаты международного мультицентрового рандомизированного двойного-слепого плацебо-контролируемого клинического исследования. Русский медицинский журнал. 2003;(5):246–9. [Laslo Kh, Melinda M, Zholt S, Ishtvan Z. Treatment of acute lumbar pain with Mydocalm. The results of an international multicenter randomized double- blind placebo-controlled clinical studies. Russkii meditsinskii zhurnal. 2003;(5):246–9. (In Russ.)].

87. Pratzel HG, Alken RG, Ramm S. Efficacy and tolerance of repeated doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial. Pain. 1996 Oct;67(2–3):417–25.

88. Кукушкин МЛ. Современный взгляд на механизм действия Мидокалма. Consilium medicum. 2013;(2):89–94. [Kukushkin ML. A modern view of the mechanism of action of Mydocalm. Consilium medicum. 2013;(2):89–94. (In Russ.)].

89. Шарапова ЕП, Алексеева ЛИ, Зайцева ЕМ и др. Применение миорелаксантов в комплексной терапии остеоартроза. Consilium medicum. 2008;(2):30–2. [Sharapova EP, Alekseeva LI, Zaitseva EM, et al. The use of muscle relaxants in the treatment of osteoarthritis. Consilium medicum. 2008;(2):30–2.[(In Russ.)].

90. Hameed F, Ihm J. Injectable medications for osteoarthritis. PMR. 2012 May;4(5 Suppl):S75–81. doi:10.1016/j.pmrj.2012.02.010. 92. Habib GS, Saliba W, Nashashibi M. Local ffects of intra-articular corticosteroids. Clin Rheumatol. 2010 Apr;29(4):347–56. doi: 10.1007/s10067-009-1357-y. Epub 2010 Jan 26.

91. Dean BJ, Lostis E, Oakley T, et al. Risks and Benefits of Glucocorticoid Treatment for Tendinopathy: A Systematic Review of the Effects of Local Glucocorticoid on Tendon. Semin Arthritis Rheum. 2014 Feb;43(4):570–6. doi: 10.1016/j.semarthrit. 2013.08.006. Epub 2013 Sep 26.

92. Tallia AF, Cardone DA.. Diagnostic and therapeutic injection of the shoulder region. Am Fam Physician. 2003 Mar 15;67(6):1271–8.

93. Coombes BK, Bisset L, Vicenzino B. Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. Lancet. 2010 Nov 20;376(9754):1751–67. doi: 10.1016/S0140- 6736(10)61160-9. Epub 2010 Oct 21.

94. Bellamy N, Campbell J, Robinson V, et al. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005328.

95. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3):363–88. doi: 10.1016/j.joca. 2014.01.003. Epub 2014 Jan 24.

96. Насонов ЕЛ, редактор. Ревматология. Клинические рекомендации. Москва: ГЭ- ОТАР-Медиа; 2010. 752 с. [Nasonov EL, editor. Revmatologiya. Klinicheskie rekomendatsii [Rheumatilogy. Clinical guidelines]. Moscow: GEOTAR-Media; 2010. 752 p.]

97. Farooq MA, Devitt AT. Perceived efficacy and risks of infection following intra-articular injections: a survey of orthopaedic surgeons. Ir J Med Sci. 2005 Jan-Mar;174(1):26–32.

98. Charalambous CP, Tryfonidis M, Sadiq S, et al. Septic arthritis following intraarticular glucocorticoid injection of the knee – a survey of current practice regarding antiseptic technique used during intra-articular glucocorticoid injection of the knee. Clin Rheumatol. 2003 Dec;22(6):386–90. Epub 2003 Oct 15.

99. Younes M, Neffati F, Touzi M, et al. Systemic effects of epidural and intra-articular glucocorticoid injections in diabetic and non-diabetic patients. Joint Bone Spine. 2007 Oct;74(5):472–6. Epub 2007 Jul 6.

100. Moon HJ, Choi KH, Lee SI, et al. Changes in blood glucose and cortisol levels after epidural or shoulder intraarticular glucocorticoid injections in diabetic or nondiabetic patients. Am J Phys Med Rehabil. 2014 May;93(5):372–8. doi: 10.1097/PHM.0000000000000001.

101. Richards BL, Whittle SL, van der Heijde DM, Buchbinder R. Efficacy and Safety of Neuromodulators in Inflammatory Arthritis: A Cochrane Systematic Review. J Rheumatol Suppl. 2012 Sep;90:28–33. doi: 10.3899/jrheum.120339.

102. Алексеева ЛИ. Препараты замедленного действия в лечении остеоартроза. Русский Медицинский Журнал. 2012;(7):389–94. [Alekseeva LI. The slowacting drugs in the treatment of osteoarthritis. Russkii Meditsinskii Zhurnal. 2012;(7):389–94. (In Russ.)].

103. Imagawa K, de Andres MC, Hashimoto K, et al. The epigenetic effect of glucosamine and a nuclear factor-kappa B (NF-κB) inhibitor on primary human chondrocytes-- implications for osteoarthritis. Biochem Biophys Res Commun. 2011 Feb 18;405(3):362–7. doi: 10.1016/j.bbrc.2011.01.007. Epub 2011 Jan 8.

104. Calamia V, Ruiz-Romero C, Rocha B, et al. Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes. Arthritis Res Ther. 2010;12(4):R138. doi: 10.1186/ar3077. Epub 2010 Jul 13.

105. Au R, Au A, Rashmir-Raven A, rondoza C. Inhibition proinflammatory gene expression n chondrocytes, monocytes, and fibroblasts by combination of avocado soybean unsaponiables, glucosamine and chondroitin sulfate. FASEB. 2007;21(6):702–7.

106. Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002946.

107. Reichenbach S, Sterchi R, Scherer M, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med. 2007 Apr 17;146(8):580–90.

108. Fidelix TS, Soares BG, Trevisani VF. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005117.

109. Christensen R, Bartels EM, Astrup A, Bliddal H. Symptomatic efficacy of vocadosoybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2008 Apr;16(4):399–408. Epub 2007 Nov 26.

110. Koes BW, van Tulder M, Lin CW, et al. An updated overview of clinical guidelines for the anagement of non-specific low back pain in primary care. Eur Spine J. 2010 Dec;19(12):2075–94.

111. Englbrecht M, Tarner IH, van der Heijde DM, et al. Measuring Pain and Efficacy of Pain Treatment in Inflammatory Arthritis: A Systematic Literature Review J Rheumatol Suppl. 2012 Sep;90:3–10. doi: 10.3899/jrheum.120335.

112. Ostelo RW, de Vet HC. Clinically important outcomes in low back pain. Best Pract Res Clin Rheumatol. 2005 Aug;19(4):593–607.

113. Stauffer ME, Taylor SD, Watson DJ, et al. Definition of nonresponse to analgesic reatment of arthritic pain: an analytical literature review of the smallest detectable ifference, the minimal detectable change, and the minimal clinically important difference n hepain visual analog scale. Int J Inflam. 2011;2011:231926. doi: 10.4061/2011/ 231926. Epub 2011 May 5.

114. Salaffi F, Stancati A, Silvestri CA, et al. Minimal clinically important changes in chronic musculoskel-etal pain intensity measured on a numerical rating scale. Eur J Pain. 2004 Aug;8(4):283–91.

115. Cepeda MS1, Africano JM, Polo R, et al. What decline in pain intensity is meaningful to patients with acute pain? Pain. 2003 Sep;105(1–2):151–7.

116. Maigne JY, Cornelis P, Chatellier G. Lower back pain and neck pain: is it possible to identify the painful side by palpation only? Ann Phys Rehabil Med. 2012 Mar;55(2):103–11. doi: 10.1016/j.rehab.2012.01.001. Epub 2012 Feb 2.


Для цитирования:


Каратеев А.Е., Алексеева Л.И. Анальгетическое лечение с использованием системного а л горитма. Современная ревматология. 2015;9(2):37-50. https://doi.org/10.14412/1996-7012-2015-2-37-50

For citation:


Karateev A.E., Alekseeva L.I. Analgesic treatment, by using a systemic algorithm. Modern Rheumatology Journal. 2015;9(2):37-50. (In Russ.) https://doi.org/10.14412/1996-7012-2015-2-37-50

Просмотров: 644


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)